153 results on '"Pastina, Pierpaolo"'
Search Results
2. Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery
3. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
4. Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
5. Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low–Middle Income Countries: A Narrative Review.
6. Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
7. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide
8. Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases
9. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT
10. The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma
11. Role of the Appropriateness of the Pelvic Lymphadenectomy and Adjuvant Radiation Therapy in Early-Stage Poorly Differentiated Endometrial Carcinoma
12. Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS)
13. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients
14. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
15. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
16. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
17. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
18. Locally advanced cervical cancer treated with chemo-radiotherapy: a case report of a particular recurrence
19. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
20. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
21. Correlation of HLA-B*35 and DRB1*11 alleles with a high risk of interstitial aseptic pneumonitis in cancer patients receiving PD-1/PDL1 immune-checkpoint blockade.
22. Radiomics predicts survival of patients with advanced non‑small cell lung cancer undergoing PD‑1 blockade using Nivolumab
23. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
24. Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.
25. Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
26. Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation
27. How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
28. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.
29. Correlation of survival of NSCLC patients given nivolumab with treatment related-eosinophilia, autoimmunity and previous bevacizumab containing regimens.
30. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine
31. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer
32. 3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures
33. Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients
34. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
35. Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy
36. P2.03a-053 Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab
37. P2.05-057 Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy
38. In Regard to Kubicek et al
39. Immunotherapy of colorectal cancer: new perspectives after a long path
40. Rolle des perilesionalen Ödems und des Tumorvolumens bei der Prognose von nicht-kleinzelligem Lungenkrebs (NSCLC) nach einer Radiochirurgie (SRS) von Hirnmetastasen.
41. Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation
42. Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial
43. Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma
44. Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients
45. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
46. Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients
47. Phase Ib study of TSPP (thymidilate synthase poly-epitope peptide) vaccine in combination with GOLFIG chemoimmuno-burst in advanced colon cancer patients: Results from the TSPP/VAC-1/c trial.
48. Abstract LB-229: Treatment of advanced cancer patients with a newest poly-epitope peptide vaccine to the thymidylate synthase(TSPP): a phase Ib (TSPP/VAC1) trial
49. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
50. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.